Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Get Help Today

Looking for help or additional information? Contact us today.
First Name:
Last Name:
Email:
Phone:
Zip Code:
Comments:
Please enter the number below:
3319
Conditions: Ovarian|Melanoma|Renal|Prostate|Colorectal|Endometrial Carcinoma|Cervical Carcinoma|Testicular Cancer|Thyroid Cancer|Small Cell Lung Carcinoma|Mesothelioma|Breast Carcinoma|Esophageal Carcinoma|Gastric Cancer|Pancreatic Carcinoma|Neuroendocrine Cancer|Liv
Start Date: February 1, 2007
Phase: Phase I
Status: Completed
NCT ID: NCT00423254
Study Type: Interventional
Intervention: Biological: PSMA/PRAME|Biological: PSMA/PRAME
Study Design: Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Results: No Results Available
Sponsors: Mannkind Corporation
Ages: Adult|Senior
Enrollment: 12
Funded By: Industry
First Received: January 12, 2007
End Date: November 1, 2009
Last Updated: August 2, 2010
Last Verified: August 1, 2010